

# Accepted Manuscript

Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies

Ahmed E. Goda, Raymond L. Erikson, Toshiyuki Sakai, Jong-Seog Ahn, Bo-Yeon Kim, Ph.D.



PII: S1574-7891(14)00205-1

DOI: [10.1016/j.molonc.2014.08.010](https://doi.org/10.1016/j.molonc.2014.08.010)

Reference: MOLONC 580

To appear in: *Molecular Oncology*

Received Date: 20 May 2014

Revised Date: 20 August 2014

Accepted Date: 21 August 2014

Please cite this article as: Goda, A.E., Erikson, R.L., Sakai, T., Ahn, J.-S., Kim, B.-Y., Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies, *Molecular Oncology* (2014), doi: 10.1016/j.molonc.2014.08.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title: Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies**

**Authors:** Ahmed E. Goda<sup>1,4</sup>, Raymond L. Erikson<sup>1,2</sup>, Toshiyuki Sakai<sup>3</sup>, Jong-Seog Ahn<sup>5</sup> and Bo-Yeon Kim<sup>1\*</sup>

**Affiliations:** <sup>1</sup>World Class Institute, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Republic of Korea.

<sup>2</sup>Department of Molecular and Cellular Biology, Harvard University, Cambridge, USA.

<sup>3</sup>Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

<sup>4</sup>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt. e-mail (AHMEDELSAYEDGODA@pharm.tanta.edu.eg).

<sup>5</sup>Chemical Biology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Republic of Korea.

**\*Corresponding Author:** Bo-Yeon Kim, Ph.D. World Class Institute, Korea Research Institute of Bioscience and Biotechnology, 685-2 Ochang, Cheongwon, 363-883, Republic of Korea. Phone : +82-43-240-6163. Fax : +82-43-240-6259. e-mail: bykim@kribb.re.kr.

**Running title:** Efficacy of bortezomib/dipyridamole combination.

**Key words:** Hematologic malignancies, dipyridamole, bortezomib, GSH/ROS, ER stress, pro-survival pathways, JAK2.

Download English Version:

<https://daneshyari.com/en/article/10914818>

Download Persian Version:

<https://daneshyari.com/article/10914818>

[Daneshyari.com](https://daneshyari.com)